Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25801788 | 0.94 | ALDH1A1 (0.36) | MAPTALDH1A1TSHR | |
| SCHEMBL25801811 | 0.93 | ALDH1A1 (0.37) | ALDH1A1MEN1KMT2A | |
| SCHEMBL25801848 | 0.92 | L3MBTL1 (0.37) | MAPTALDH1A1KMT2AL3MBTL1KDM4E | |
| SCHEMBL23578414 | 0.88 | TP53 (0.38) | MAPTALDH1A1TSHRHDAC6MEN1 | |
| SCHEMBL23578571 | 0.88 | MAPT (0.35) | MAPTALDH1A1TSHRHDAC6MEN1 | |
| SCHEMBL23578197 | 0.88 | MAPT (0.47) | MAPTALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL25801910 | 0.88 | MAPT (0.41) | MAPTALDH1A1HDAC6KDM4E | |
| SCHEMBL23578154 | 0.86 | MEN1 (0.40) | MEN1KMT2A | |
| SCHEMBL23578222 | 0.86 | L3MBTL1 (0.37) | ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL23588107 | 0.85 | MAPT (0.45) | MAPTALDH1A1TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| EP-4081511-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | Sitryx Therapeutics Limited (GB) | 2022-11-02 | — | — | EP | disclosed |
| CN-115066418-A | Carboxy derivatives with anti-inflammatory properties | 西特瑞治疗有限公司 | 2022-09-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | CPA2, RO60, C5AR1 | MAPT 4683/4885ALDH1A1 134/4885TSHR 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.